Mast Cell Stabilizers Market
Number of pages: 100 | Report Format: PDF | Published date: June 22, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 2.05 billion |
|
Revenue Forecast in 2031 |
US$ 3.62 billion |
|
CAGR |
6.5% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global mast cell stabilizers market was valued at US$ 2.05 billion in 2022 and is expected to register a revenue CAGR of 6.5% to reach US$ 3.62 billion by 2031.
Mast Cell Stabilizers Market Fundamentals
Mast cell stabilizers are a class of medications used to treat allergic conditions, particularly those involving the respiratory system and the eyes. The medication works by preventing the release of histamine from mast cells, which is involved in allergic reactions. These medications assist in decreasing the severity and symptoms of allergic responses by stabilizing mast cells.
The global mast cell stabilizers market has many potential trends and opportunities. For instance, there is ongoing research and development in the field of drug delivery systems, including inhalers, nasal sprays, and eye drops. Innovations in these areas can lead to more efficient and convenient administration of mast cell stabilizers, enhancing patient compliance and treatment outcomes. The demand for mast cell stabilizers is anticipated to increase in the upcoming years due to the growing geriatric population and the rising prevalence of allergies as well as chronic disorders.
Personalized medicine is making progress through genetic profiling and biomarker identification, which can pave the way for personalized treatment approaches for allergic ailments. This might involve customizing mast cell stabilizer treatments based on a person's unique allergy triggers or genetic factors, resulting in a more precise and effective treatment choice.
The players in the mast cell stabilizers market employ various strategies to increase their revenue. Companies invest in research and development to create new and improved mast cell stabilizer formulations, delivery systems, and combination therapies. By introducing innovative products with enhanced efficacy, safety, and patient convenience, market players can attract more customers and capture a larger market share.
Mast Cell Stabilizers Market Dynamics
The rising prevalence of allergic conditions, such as asthma, allergic rhinitis, and atopic dermatitis, is a significant driver for the mast cell stabilizers market and is the key factor in increasing the mast cell stabilizers market. According to American Academy of Allergy Asthma & Immunology, It is estimated that in 2022 allergic rhinitis affected around 10% to 30% of the U.S. population. Similarly, there has been a significant rise in the number of people affected by asthma. According to the Asthma and Allergy Foundation of America, approximately 26 million individuals in the United States have asthma in 2022, roughly 1 in 13 people. Additionally, nearly 21 million adults aged 18 and above in the U.S. have asthma. This trend is expected to continue in the coming years due to various factors such as air pollution, climate change, and genetic predisposition.
Moreover, the presence of many pipeline mast cell stabilizers drugs in the market is anticipated to increase the global mast cell stabilizers market. For instance, the University of California, San Francisco is researching the efficacy of montelukast in treating mast cell activation syndrome (MCAS). In this condition, mast cells are overactive and cause various symptoms such as flushing, abdominal pain, and fatigue. Montelukast, currently used to treat asthma and allergies, is a leukotriene receptor antagonist that can also inhibit mast cell activation. This ongoing research on montelukast for MCAS treatment is expected to drive the demand for mast cell stabilizers in the coming years.
Restraining factors in the mast cell stabilizers market include the limited availability of drugs in certain regions and the lack of awareness among patients regarding the benefits of these drugs. Additionally, the high cost of treatment and the adverse effects associated with some drugs may also hinder market growth.
Mast Cell Stabilizers Market Ecosystem
The global mast cell stabilizers market is analyzed from the following perspectives: type, end user, and region.
Mast Cell Stabilizers Market by Indications
Based on indications, the global mast cell stabilizers market is segmented into mastocytosis, seasonal allergic rhinitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis (vkc), asthma, allergic conjunctivitis, and others.
The asthma segment accounted for most of the global mast cell stabilizers market revenue share in 2022. This is due to the increasing prevalence of asthma and the effectiveness of mast cell stabilizers in managing asthma symptoms. As per the Asthma and Allergy Foundation of America, around 26 million individuals in the United States will be dealing with asthma in 2022, which makes up roughly 1 in 13 people. Furthermore, almost 21 million adults aged 18 and above in the U.S. are affected by asthma. The foundation also states that asthma affects more females than males, with 9.7% of female adults and 6.2% of male adults. Asthma is a major chronic disease in children, with approximately 4.8 million children under 18 currently affected. In addition, the rising awareness among patients and healthcare professionals regarding the benefits of mast cell stabilizers is also contributing to the growth of this segment. Moreover, the development of new and improved mast cell stabilizers is also expected to drive the market growth in the near future.
Mast Cell Stabilizers Market by End User
Based on the end user, the global mast cell stabilizers market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounts for the majority of the global mast cell stabilizers market share. This is due to the high patient footfall of asthma and allergy patients to hospitals. In addition, hospitals often stock a variety of medications to treat various conditions, including mast cell stabilizers. Furthermore, hospital pharmacies have larger purchasing power, which allows them to negotiate better prices with suppliers and distributors. As a result, many patients prefer to purchase their medications from hospital pharmacies, further driving the growth of the mast cell stabilizers market in this segment.
Mast Cell Stabilizers Market by Region
Based on the region, the mast cell stabilizers market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The increasing prevalence of obesity and sedentary lifestyles in the region is the key factor driving the growth of North America market. The National Institute of Diabetes and Kidney Diseases reports that 42% of American adults are considered obese, while approximately 30.7% are classified as overweight. Over two-thirds of adults in the United States are overweight or obese. Additionally, the high disposable income of consumers in North America has led to a rise in demand for cosmetic treatments, including cellulite reduction procedures. The growing popularity of non-invasive and minimally invasive treatments is also contributing to the expansion of the market in the region. The United States is expected to remain the largest market for cellulite treatment in North America, owing to the presence of a large number of cosmetic clinics and advanced healthcare infrastructure.
The Asia Pacific mast cell stabilizers market is anticipated to register high revenue CAGR at 7.3%. This growth can be attributed to the region's increasing prevalence of allergies and asthma. According to the World Allergy Organization, Asia Pacific has a high burden of allergic diseases, with up to 40% of the population affected. Additionally, the availability of a variety of cost-effective generic versions of these drugs is expected to boost further the revenue growth of the global mast cell stabilizers market. Moreover, the growing awareness about the benefits of early diagnosis and treatment of allergies is also contributing to the market revenue growth.
Mast Cell Stabilizers Market Competitive Landscape
The mast cell stabilizers market is highly competitive, with the presence of several key players. These players constantly engage in research and development activities to introduce innovative products and gain a competitive edge. Additionally, mergers and acquisitions, partnerships, and collaborations are common strategies players adopt to expand their market share. The increasing prevalence of allergic diseases and the growing demand for effective treatment options are expected to intensify market competition.
Some of the prominent companies having the largest revenue share in the global Mast Cell Stabilizers Market are,
Mast cell stabilizers are a class of medications used to treat allergic conditions, particularly those involving the respiratory system and the eyes.
The global mast cell stabilizers market has been growing steadily over the years. This growth can be attributed to factors such as a significant increase in the prevalence of allergies and asthma and the introduction of new drugs in the mast cell stabilizers market.
The global mast cell stabilizers market is expected to register a revenue CAGR of 6.5% in the forecast period from 2022 to 2031.
North America accounted for most of the global mast cell stabilizers market, with the majority of market revenue share in 2022. This is due to the presence of a high patient pool and the presence of many top market players.
The global mast cell stabilizers market was valued at US$ 2.05 Billion in 2022.
*Insights on financial performance are subject to the availability of information in the public domain